{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:49:07Z","timestamp":1793332147164,"version":"4.5.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.neurol.2018.03.006","type":"journal-article","created":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T01:57:37Z","timestamp":1524103057000},"page":"358-363","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"title":["Progress in understanding the pathophysiology of multiple sclerosis"],"prefix":"10.1016","volume":"174","author":[{"given":"H.","family":"Z\u00e9phir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Apr (4)","key":"10.1016\/j.neurol.2018.03.006_bib0340","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2018.03.006_bib0345","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature10251","article-title":"Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis","volume":"476","author":"International Multiple Sclerosis Genetics Consortium","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.neurol.2018.03.006_bib0350","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri3871","article-title":"Immunopathology of multiple sclerosis","volume":"15","author":"Dendrou","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.neurol.2018.03.006_bib0355","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/brain\/awp070","article-title":"The relation between inflammation and neurodegeneration in multiple sclerosis brains","volume":"132","author":"Frischer","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2018.03.006_bib0360","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.it.2012.07.004","article-title":"Capture, crawl, cross: the T cell code to breach the blood-brain barriers","volume":"33","author":"Engelhardt","year":"2012","journal-title":"Trends Immunol"},{"key":"10.1016\/j.neurol.2018.03.006_bib0365","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nri3391","article-title":"Orchestrated leukocyte recruitment to immune-privileged sites: absolute barriers versus educational gates","volume":"13","author":"Shechter","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"Suppl 1","key":"10.1016\/j.neurol.2018.03.006_bib0370","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0022-510X(01)00485-3","article-title":"The role of non-conventional MR techniques to study multiple sclerosis patients","volume":"186","author":"Rovaris","year":"2001","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurol.2018.03.006_bib0375","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1093\/brain\/awg261","article-title":"Primary progressive multiple sclerosis: a 5-year clinical and MR study","volume":"126","author":"Ingle","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2018.03.006_bib0380","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/brain\/121.1.103","article-title":"Imaging axonal damage of normal-appearing white matter in multiple sclerosis","volume":"121","author":"Fu","year":"1998","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2018.03.006_bib0385","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nri2554","article-title":"From genes to function: the next challenge to understanding multiple sclerosis","volume":"9","author":"Fugger","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.neurol.2018.03.006_bib0390","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrneurol.2014.37","article-title":"Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis","volume":"10","author":"Friese","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurol.2018.03.006_bib0395","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2377-12-11","article-title":"Meningeal and cortical grey matter pathology in multiple sclerosis","volume":"12","author":"Popescu","year":"2012","journal-title":"BMC Neurol"},{"key":"10.1016\/j.neurol.2018.03.006_bib0400","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1038\/ng.2770","article-title":"Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis","volume":"45","author":"International Multiple Sclerosis Genetics Consortium (IMSGC)","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.neurol.2018.03.006_bib0405","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1177\/1352458511433920","article-title":"Epstein-Barr virus neutralizing antibody levels and risk of multiple sclerosis","volume":"18","author":"Simon","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2018.03.006_bib0410","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1474-4422(14)70267-4","article-title":"Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses","volume":"14","author":"Belbasis","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2018.03.006_bib0415","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/ng.3395","article-title":"Class II HLA interactions modulate genetic risk for multiple sclerosis","volume":"47","author":"Moutsianas","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.neurol.2018.03.006_bib0420","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1365-2249.2010.04121.x","article-title":"99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: Epstein-Barr virus and multiple sclerosis: epidemiological evidence","volume":"160","author":"Ascherio","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.neurol.2018.03.006_bib0425","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1002\/eji.201444662","article-title":"High-throughput sequencing of TCR repertoires in multiple sclerosis reveals intrathecal enrichment of EBV-reactive CD8+ T cells","volume":"44","author":"Lossius","year":"2014","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.neurol.2018.03.006_bib0430","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.immuni.2008.07.017","article-title":"Memory inflation during chronic viral infection is maintained by continuous production of short-lived, functional T cells","volume":"29","author":"Snyder","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.neurol.2018.03.006_bib0435","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0b013e3181d865a1","article-title":"Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis","volume":"74","author":"Sargsyan","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2018.03.006_bib0440","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nri2527","article-title":"Antiviral immune responses: triggers of or triggered by autoimmunity?","volume":"9","author":"M\u00fcnz","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.neurol.2018.03.006_bib0445","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1093\/brain\/awm198","article-title":"Parental smoking at home and the risk of childhood-onset multiple sclerosis in children","volume":"130","author":"Mikaeloff","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2018.03.006_bib0450","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature10554","article-title":"Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination","volume":"479","author":"Berer","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.neurol.2018.03.006_bib0455","doi-asserted-by":"crossref","first-page":"10719","DOI":"10.1073\/pnas.1711233114","article-title":"Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice","volume":"114","author":"Berer","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurol.2018.03.006_bib0460","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1073\/pnas.1000082107","article-title":"Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis","volume":"108","author":"Lee","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurol.2018.03.006_bib0465","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1007\/s00018-016-2175-4","article-title":"Modulatory effects of \u03b17 nAChRs on the immune system and its relevance for CNS disorders","volume":"73","author":"Kalkman","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.neurol.2018.03.006_bib0470","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.phrs.2017.10.005","article-title":"Nicotine and autoimmunity: the lotus\u2019 flower in tobacco","volume":"128","author":"Gomes","year":"2018","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.neurol.2018.03.006_bib0475","doi-asserted-by":"crossref","first-page":"10713","DOI":"10.1073\/pnas.1711235114","article-title":"Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models","volume":"114","author":"Cekanaviciute","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurol.2018.03.006_bib0480","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3389\/fmicb.2011.00166","article-title":"Modulation of mucosal immune response, tolerance, and proliferation in mice colonized by the Mucin-Degrader Akkermansia muciniphila","volume":"2","author":"Derrien","year":"2011","journal-title":"Front Microbiol"},{"key":"10.1016\/j.neurol.2018.03.006_bib0485","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1600-065X.2012.01132.x","article-title":"Bridging the gap from genetic association to functional understanding: the next generation of mouse models of multiple sclerosis","volume":"248","author":"Attfield","year":"2012","journal-title":"Immunol Rev"},{"key":"10.1016\/j.neurol.2018.03.006_bib0490","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40265-014-0212-x","article-title":"Teriflunomide and its mechanism of action in multiple sclerosis","volume":"74","author":"Bar-Or","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.neurol.2018.03.006_bib0495","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.clim.2011.02.017","article-title":"Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of action","volume":"142","author":"Gold","year":"2012","journal-title":"Clin Immunol"},{"key":"10.1016\/j.neurol.2018.03.006_bib0500","first-page":"74","article-title":"Mitoxantrone in the treatment of multiple sclerosis","volume":"12","author":"Morrissey","year":"2005","journal-title":"Int MS J"},{"key":"10.1016\/j.neurol.2018.03.006_bib0505","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1212\/01.WNL.0000158329.30470.D0","article-title":"Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale","volume":"64","author":"Rice","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2018.03.006_bib0510","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1345\/aph.1G424","article-title":"Fingolimod: a novel immunosuppressant for multiple sclerosis","volume":"41","author":"Brown","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.neurol.2018.03.006_bib0515","doi-asserted-by":"crossref","first-page":"16414","DOI":"10.3390\/ijms160716414","article-title":"Alemtuzumab in multiple sclerosis: mechanism of action and beyond","volume":"16","author":"Ruck","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.neurol.2018.03.006_bib0520","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1007\/s13311-017-0553-8","article-title":"Daclizumab: development, clinical trials, and practical aspects of use in multiple sclerosis","volume":"14","author":"Baldassari","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurol.2018.03.006_bib0525","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2018.03.006_bib0530","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/ana.21757","article-title":"Real-life impact of early interferon beta therapy in relapsing multiple sclerosis","volume":"66","author":"Trojano","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2018.03.006_bib0535","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2018.03.006_bib0540","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nm.2324","article-title":"A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis","volume":"17","author":"Niki\u0107","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.neurol.2018.03.006_bib0545","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.neuron.2014.11.006","article-title":"Pervasive axonal transport deficits in multiple sclerosis models","volume":"84","author":"Sorbara","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.neurol.2018.03.006_bib0550","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/brain\/awq076","article-title":"Evidence for a two-stage disability progression in multiple sclerosis","volume":"133","author":"Leray","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2018.03.006_bib0555","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/jnen\/61.10.914","article-title":"Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats","volume":"61","author":"Proescholdt","year":"2002","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.neurol.2018.03.006_bib0560","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.immuni.2015.11.022","article-title":"The origin of tissue-resident macrophages: when an erythro-myeloid progenitor is an erythro-myeloid progenitor","volume":"43","author":"Perdiguero","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.neurol.2018.03.006_bib0565","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/B978-0-444-52001-2.00002-9","article-title":"Pathology of multiple sclerosis and related inflammatory demyelinating diseases","volume":"122","author":"Kutzelnigg","year":"2014","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.neurol.2018.03.006_bib0570","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/brain\/awm038","article-title":"Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology","volume":"130","author":"Magliozzi","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2018.03.006_bib0575","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/brain\/122.1.17","article-title":"Cortical lesions in multiple sclerosis","volume":"122","author":"Kidd","year":"1999","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2018.03.006_bib0580","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/ana.1123","article-title":"Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions","volume":"50","author":"Peterson","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2018.03.006_bib0585","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1191\/1352458503ms917oa","article-title":"Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration","volume":"9","author":"B\u00f8","year":"2003","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2018.03.006_bib0590","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ana.21240","article-title":"Multiple sclerosis and Alzheimer's disease","volume":"63","author":"Dal Bianco","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2018.03.006_bib0595","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/ana.22230","article-title":"A gradient of neuronal loss and meningeal inflammation in multiple sclerosis","volume":"68","author":"Magliozzi","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2018.03.006_bib0600","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"issue":"1351","key":"10.1016\/j.neurol.2018.03.006_bib0605","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.brainres.2010.07.026","article-title":"Visual evoked potentials and MBP gene expression imply endogenous myelin repair in adult rat optic nerve and chiasm following local lysolecithin induced demyelination","author":"Mozafari","year":"2010","journal-title":"Brain Res"},{"key":"10.1016\/j.neurol.2018.03.006_bib0610","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1093\/brain\/awq250","article-title":"Demyelination versus remyelination in progressive multiple sclerosis","volume":"133","author":"Bramow","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2018.03.006_bib0615","doi-asserted-by":"crossref","DOI":"10.1002\/ana.24620","article-title":"Dynamic imaging of individual remyelination profiles in multiple sclerosis","author":"Bodini","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2018.03.006_bib0620","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/ana.23693","article-title":"Cortical remyelination: a new target for repair therapies in multiple sclerosis","volume":"72","author":"Chang","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2018.03.006_bib0625","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.stem.2011.11.019","article-title":"Rejuvenation of regeneration in the aging central nervous system","volume":"10","author":"Ruckh","year":"2012","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.neurol.2018.03.006_bib0630","doi-asserted-by":"crossref","first-page":"948976","DOI":"10.1155\/2013\/948976","article-title":"The benefits and detriments of macrophages\/microglia in models of multiple sclerosis","volume":"2013","author":"Rawji","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.neurol.2018.03.006_bib0635","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/brain\/120.3.393","article-title":"Axonal damage in acute multiple sclerosis lesions","volume":"120","author":"Ferguson","year":"1997","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2018.03.006_bib0640","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1093\/brain\/122.12.2279","article-title":"A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases","volume":"122","author":"Lucchinetti","year":"1999","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2018.03.006_bib0645","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/brain\/awh714","article-title":"Age at disability milestones in multiple sclerosis","volume":"129","author":"Confavreux","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2018.03.006_bib0650","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ana.24497","article-title":"Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque","volume":"78","author":"Frischer","year":"2015","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2018.03.006_bib0655","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/(SICI)1098-1136(199910)28:1<77::AID-GLIA9>3.0.CO;2-F","article-title":"Remyelination occurs as extensively but more slowly in old rats compared to young rats following gliotoxin-induced CNS demyelination","volume":"28","author":"Shields","year":"1999","journal-title":"Glia"},{"key":"10.1016\/j.neurol.2018.03.006_bib0660","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.neurobiolaging.2005.06.008","article-title":"Differences in the early inflammatory responses to toxin-induced demyelination are associated with the age-related decline in CNS remyelination","volume":"27","author":"Zhao","year":"2006","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.neurol.2018.03.006_bib0665","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nn1460","article-title":"LINGO-1 negatively regulates myelination by oligodendrocytes","volume":"8","author":"Mi","year":"2005","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.neurol.2018.03.006_bib0670","series-title":"Abstract 231, ECTRIMS","article-title":"Evidence that the anti-LINGO-1 monoclonal antibody BIIB033 protects against multifocal visual evoked potential amplitude loss in the fellow eye of subjects with unilateral acute optic neuritis","author":"Cadavid","year":"2015"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378717308597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378717308597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T04:17:43Z","timestamp":1720239463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378717308597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":67,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0035378717308597"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2018.03.006","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progress in understanding the pathophysiology of multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2018.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}